A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients

Kidney transplant recipients receiving calcineurin inhibitor-based immunosuppression incur increased long-term risks of cancer and kidney fibrosis. Switch to mammalian target of rapamycin (mTOR) inhibitors may reduce these risks. Steroid or Cyclosporin Removal After Transplant using Everolimus (SOCR...

Descripción completa

Detalles Bibliográficos
Autores principales: Chadban, Steven J, Eris, Josette Marie, Kanellis, John, Pilmore, Helen, Lee, Po Chang, Lim, Soo Kun, Woodcock, Chad, Kurstjens, Nicol, Russ, Graeme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282427/
https://www.ncbi.nlm.nih.gov/pubmed/24279685
http://dx.doi.org/10.1111/tri.12252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282427/
https://www.ncbi.nlm.nih.gov/pubmed/24279685
http://dx.doi.org/10.1111/tri.12252

Ejemplares similares